Altered Expression of ARP2/3 Complex Signaling Pathway Genes in Prefrontal Layer 3 Pyramidal Cells in Schizophrenia
Publication: American Journal of Psychiatry
Abstract
Objective:
Lower dendritic spine density on layer 3 pyramidal cells in the dorsolateral prefrontal cortex (DLPFC) appears to contribute to cognitive dysfunction in schizophrenia, whereas psychosis is associated with excessive dopamine release in the striatum. These findings may be related via excitatory projections from the DLPFC to the ventral mesencephalon, the location of dopamine cells projecting to the striatum. Consistent with this hypothesis, deletion of the actin-related protein-2/3 (ARP2/3) complex, which regulates the actin cytoskeleton supporting dendritic spines, produced spine loss in cortical pyramidal cells and striatal hyperdopaminergia in mice. The authors sought to determine whether the ARP2/3 complex is altered in schizophrenia.
Method:
In matched pairs of schizophrenia and comparison subjects, transcript levels of ARP2/3 complex signaling pathway were assessed in laser-microdissected DLPFC layer 3 and 5 pyramidal cells and layer 3 parvalbumin interneurons, and in total DLPFC gray matter.
Results:
Transcript levels of ARP2/3 complex subunits and of nucleation promotion factors that regulate the ARP2/3 complex were significantly lower in DLPFC layer 3 and 5 pyramidal cells in schizophrenia. In contrast, these transcripts were unaltered, or only modestly changed, in parvalbumin interneurons and DLPFC gray matter.
Conclusions:
Down-regulation of the ARP2/3 complex signaling pathway, a common final pathway for multiple signaling cascades that regulate the actin cytoskeleton, would compromise the structural stability of spines, leading to their loss. In concert with findings from deletion of the ARP2/3 complex in mice, these findings support the idea that spine deficits in the DLPFC may contribute to subcortical hyperdopaminergia in schizophrenia.
Cognitive deficits constitute a core feature of schizophrenia (1), are persistent across the course of the illness (2), and are the best predictor of long-term functional outcome (3). At least some of these deficits arise during childhood and adolescence, before the onset of the psychosis associated with a clinical diagnosis of schizophrenia (4).
The impairments in certain cognitive processes, such as working memory, appear to reflect alterations in specific elements of dorsolateral prefrontal cortex (DLPFC) circuitry known to be critical for working memory in primates (5). For example, reciprocal excitatory connections among DLPFC layer 3 pyramidal cells are thought to mediate sustained neuronal activity during the maintenance phase of working memory in monkeys (6); in individuals with schizophrenia, these neurons have fewer dendritic spines, the principal site of glutamatergic inputs (7). In contrast, the psychotic symptoms of schizophrenia are associated with excessive dopamine release in the associative striatum (8).
These two domains of schizophrenia pathology and pathophysiology have been hypothesized to be related via the excitatory projections from the DLPFC to the ventral mesencephalon, the location of the dopamine cells that project to the striatum (9). That is, the deficit in dendritic spines, and the resulting reduction in excitatory drive to DLPFC pyramidal cells, is thought to lead to the hyperdopaminergic state subcortically (10). Consistent with this hypothesis, conditional deletion in mice of the actin-related protein-2/3 (ARP2/3) complex, which acts as a common final pathway for multiple signaling cascades that regulate the actin cytoskeleton required for dendritic spine formation and maintenance (11, 12), was shown to produce a loss of dendritic spines in prefrontal cortical pyramidal cells and elevated striatal dopamine neurotransmission (13). These changes were accompanied by cognitive deficits and antipsychotic-responsive locomotor hyperactivity (13, 14). The idea that a spine deficit in prefrontal cortical pyramidal neurons was the upstream cause of increased subcortical dopamine was supported by proof-of-concept evidence that viral re-expression of the ARP2/3 complex in frontal cortical pyramidal neurons lowers striatal dopamine levels and reduces locomotor hyperactivity (13).Together, these findings provide a mechanistic basis for the prior observation that diminished activity in the DLPFC predicts subcortical hyperdopaminergia in schizophrenia (15). However, it is not known whether expression of the ARP2/3 complex in DLPFC pyramidal cells is deficient in schizophrenia.
The goal of the present study was to examine the ARP2/3 complex signaling pathway (Figure 1A) in DLPFC deep layer 3 pyramidal cells, where dendritic spine alterations are most pronounced in schizophrenia (16, 17). We used laser microdissection to capture individual pyramidal cells in DLPFC deep layer 3 from subjects with schizophrenia and matched unaffected comparison subjects and assessed gene expression in pools of neurons from each subject by microarray analysis. In order to assess the cell-type specificity of the findings, we analyzed microarray data from layer 5 pyramidal cells and layer 3 parvalbumin interneurons, and we measured expression levels of certain transcripts in total DLPFC gray matter using quantitative reverse-transcription polymerase chain reaction (qPCR). In each analysis, we evaluated transcript levels for all subunits of the ARP2/3 complex and of nucleation promotion factors that regulate the activity of the ARP2/3 complex (Figure 1A).
FIGURE 1. Schematic Illustration of the ARP2/3 Complex Signaling Pathway and Contribution to Spine Deficits in Schizophreniaa
a Panel A depicts nucleation promotion factors (NPFs) that regulate the activity of the ARP2/3 complex in a healthy state. NPFs include Neural Wiskott-Aldrich syndrome (N-WASP) protein encoded by WASL, WASP family Verprolin-homologous (WAVE) proteins, cytoplasmic FMR1 interacting protein I (CYFIP1), and cortactin, which act downstream of Rho GTPases such as CDC42 and RAC. Activation of the ARP2/3 complex by multiple nucleation promotion factors results in actin nucleation and polymerization to generate F-actin branched filaments from existing F-actin monomers. Arrows indicate activation. Panel B illustrates the molecular cascades of ARP2/3 complex dysregulation in schizophrenia. The marked decrement in mRNA levels for CYFIP1, cortactin, and N-WASP and ARP2/3 complex subunits in dorsolateral prefrontal cortex layer 3 pyramidal cells converge to decrease F-actin nucleation and polymerization required for spine growth and maintenance, contributing to spine deficits.
Method
Human Subjects
Brain specimens (N=124) were obtained during routine autopsies conducted at the Allegheny County Office of the Medical Examiner (Pittsburgh) after consent was obtained from next of kin (18). Subject groups for the entire cohort (N=62 pairs; for individual subject details, see Table S1 in the data supplement that accompanies the online edition of this article), as well as for the subsets of pairs used in specific studies, did not differ significantly in mean age, postmortem interval, RNA integrity number (Agilent Bioanalyzer, Santa Clara, Calif.), tissue storage time at −80°C, or race (Table 1). Mean brain pH was significantly different between subject groups for the entire cohort (t=2.6, df=122, p=0.01), but the difference was quite small (0.1 pH unit) and of uncertain biological significance. All procedures were approved by the University of Pittsburgh’s Committee for the Oversight of Research and Clinical Trials Involving the Dead and Institutional Review Board for Biomedical Research.
| Microarray (Pyramidal Cells) | Microarray (Parvalbumin Cells) | qPCR (Gray Matter) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Comparison Group (N=36) | Schizophrenia Group (N=36) | Comparison Group (N=14) | Schizophrenia Group (N=14) | Comparison Group (N=62) | Schizophrenia Group (N=62) | ||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |
| Male | 27 | 75 | 27 | 75 | 10 | 71.4 | 10 | 71.4 | 47 | 75.8 | 47 | 75.8 |
| Race | ||||||||||||
| White | 30 | 83.3 | 24 | 66.7 | 12 | 85.7 | 10 | 71.4 | 52 | 83.9 | 46 | 74.2 |
| Black | 6 | 16.7 | 12 | 33.3 | 2 | 14.3 | 4 | 28.6 | 10 | 16.1 | 16 | 25.8 |
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| Age (years) | 48.1 | 13.0 | 46.9 | 12.4 | 46.7 | 11.3 | 44.3 | 11.2 | 48.7 | 13.8 | 47.7 | 12.7 |
| Postmortem interval (hours) | 17.6 | 6.1 | 18.0 | 8.8 | 17.1 | 6.6 | 17.7 | 8.4 | 18.8 | 5.5 | 19.2 | 8.5 |
| RNA integrity number | 8.3 | 0.6 | 8.2 | 0.6 | 7.8 | 0.5 | 7.8 | 0.5 | 8.2 | 0.6 | 8.1 | 0.6 |
| Brain pH | 6.7 | 0.2 | 6.6 | 0.4 | 6.7 | 0.2 | 6.4 | 0.2 | 6.7 | 0.2 | 6.6 | 0.3 |
| Storage time (months) | 122.2 | 49.8 | 125.7 | 53.1 | 91.7 | 22.4 | 85.2 | 9.6 | 152.8 | 56.5 | 149.1 | 60.9 |
a
No significant differences in between-group comparisons within each type of analysis, except for brain pH in parvalbumin cells (t=4.3, df=26, p<0.001) and in gray matter (t=2.6, df=122, p=0.01). qPCR=quantitative polymerase chain reaction.
Laser Microdissection Procedure
As described previously (19, 20), cryostat sections (12 μm) containing DLPFC area 9 were thaw-mounted onto glass PEN membrane slides (Leica Microsystems, Bannockburn, Ill.) and stained for Nissl substance with thionin. Using a Leica laser microdissection system, DLPFC deep layer 3 and layer 5 were identified in portions of the section cut perpendicular to the pial surface. Nissl-stained pyramidal neurons, identified by their characteristic triangular shape and prominent apical dendrite, were individually dissected from each laminar location. Parvalbumin interneurons were identified by dual labeling of NeuN-positive interneurons and Vicia villosa agglutinin (VVA) labeling of perineuronal nets in layers 3 and 4 (21).
Microarray Analyses
For pyramidal cell microarray analyses (19, 21), 200 DLPFC pyramidal cells from deep layer 3 and from layer 5 were dissected individually and then pooled together by layer for each subject (N=36 pairs) (19). Array results were not readable for layer 5 samples from two schizophrenia subjects, and thus two subject pairs were excluded. For parvalbumin interneuron microarray analyses, 360 parvalbumin interneurons were dissected from 14 of the 36 subject pairs (21). The cDNA from each sample was loaded on an Affymetrix GeneChip HT HG-U133+ PM Array plate (Affymetrix, Santa Clara, Calif.) designed to assess transcript levels from the human genome.
We also used microarray analyses to evaluate ARP2/3 complex signaling pathway transcripts in DLPFC deep layer 3 pyramidal cells from monkeys with chronic exposure to olanzapine, haloperidol, or placebo (see the Supplementary Methods section in the online data supplement ).
qPCR
For each subject in the full cohort (N=62 pairs), area 9 gray matter was collected and cDNA prepared as previously described (18) (see the Supplementary Methods section in the data supplement ). Based on their stable levels of expression across schizophrenia and comparison subjects, three reference genes (beta-actin, cyclophilin-A, and glyceraldehyde-3-phosphate dehydrogenase [GAPDH]) were used to normalize target mRNA levels. The difference in cycle threshold (dCT) for each target transcript was calculated by subtracting the geometric mean CT of the three reference genes from the CT of the target transcript. Since dCT represents the log2-transformed expression ratio of each target transcript to the reference genes, the relative level of the target transcript for each subject is reported as 2−dCT.
Data Analysis
A comprehensive description of the statistical analyses used for the microarray data is provided by Arion et al. (19). Briefly, Affymetrix CEL files were normalized and log2-transformed using RMA Express. After filtering to remove uninformative probe sets, the random intercept model with Bayesian information criterion variable selection (RIM-BIC) was used to analyze the microarray data set. An adaptively weighted Fisher’s method was used to combine the differential expression information for each transcript, and the Benjamini-Hochberg protocol was used to control the false discovery rate (<0.05) for the meta-analyzed p values.
In a separate analysis, the microarray signals for all probe sets targeting each ARP2/3 complex transcript were averaged within each sample and used in two analysis of covariance (ANCOVA) models. The paired ANCOVAs used the level of each mRNA as the dependent variable, diagnostic group as the main effect, subject pair as a blocking factor, and postmortem interval, storage time, brain pH, and RNA integrity number as covariates. However, subject pairing may be considered an attempt to account for the parallel processing of tissue samples from a pair and to balance diagnostic groups for sex and age, and thus not to be a true statistical paired design. Consequently, we also used an unpaired ANCOVA that included age, sex, postmortem interval, storage time, brain pH, and RNA integrity number as covariates. These same two models were used to analyze the data from the qPCR analyses. Because the two models gave the same results with regard to statistical significance, only the results from the unpaired model are presented here (for the paired model results, see Table S3 in the online data supplement ).
The influence of comorbid factors on ARP2/3 complex signaling pathway transcript expression was assessed by ANCOVA (see the Supplementary Methods section in the data supplement ).
For all ANCOVAs, reported statistics include only the covariates that were statistically significant. As a result, the reported degrees of freedom vary across analyses.
Results
Expression Levels of ARP2/3 Complex Signaling Pathway Genes in DLPFC Deep Layer 3 Pyramidal Cells in Schizophrenia
Using a false discovery rate of 5%, seven of the 12 transcripts in the ARP2/3 complex signaling pathway were significantly down-regulated in DLPFC deep layer 3 pyramidal cells from schizophrenia subjects, and another three transcripts showed a nonsignificant (p<0.09) down-regulation (Table 2). Because a number of transcripts were represented on the Affymetrix array by more than one probe set, the microarray signal for redundant probe sets was averaged within each sample. The resulting mRNA levels were compared between subject groups by ANCOVA as described in the following paragraphs.
| ARP2/3 Complex Signaling Pathway Transcripts | Probe Sets | % Change in Layer 3 Pyramidal Cells | p | % Change in Layer 5 Pyramidal Cells | p |
|---|---|---|---|---|---|
| ACTR2 | 1554390_PM_s_at | –11.38 | 0.006 | –12.66 | 0.011 |
| 1558015_PM_s_at | –10.41 | 0.006 | –11.82 | 0.025 | |
| 200729_PM_s_at | –7.68 | 0.105 | –8.39 | 0.147 | |
| ACTR3 | 200996_PM_at | –19.50 | 0.001 | –23.79 | 0.000 |
| 213101_PM_s_at | –12.67 | 0.002 | –14.32 | 0.014 | |
| 213102_PM_at | –13.12 | 0.001 | –17.28 | 0.002 | |
| ARPC1A | 200950_PM_at | 3.67 | 0.478 | 2.66 | 0.701 |
| ARPC1B | 201954_PM_at | –4.50 | 0.302 | –2.29 | 0.539 |
| ARPC2 | 207988_PM_s_at | –17.63 | 0.002 | –21.18 | 0.001 |
| 208679_PM_s_at | –22.41 | 0.003 | –25.41 | 0.011 | |
| 213513_PM_x_at | –3.85 | 0.131 | –2.44 | 0.424 | |
| ARPC3 | 208736_PM_at | –15.99 | 0.001 | –16.88 | 0.005 |
| ARPC4 | 211672_PM_s_at | –11.70 | 0.003 | –10.57 | 0.162 |
| 217817_PM_at | –14.00 | 0.001 | –16.57 | 0.001 | |
| 217818_PM_s_at | –7.83 | 0.009 | –3.50 | 0.395 | |
| ARPC5 | 211963_PM_s_at | –11.84 | 0.031 | –22.40 | 0.008 |
| 1555797_PM_a_at | –8.43 | 0.051 | –6.43 | 0.190 | |
| CTTN | 201059_PM_at | –11.33 | 0.066 | –14.09 | 0.041 |
| 214073_PM_at | –21.23 | 0.109 | –38.45 | 0.008 | |
| WASL | 224813_PM_at | –10.38 | 0.028 | –13.11 | 0.051 |
| 230340_PM_s_at | –12.30 | 0.044 | –22.25 | 0.004 | |
| 205809_PM_s_at | –7.55 | 0.225 | –18.36 | 0.021 | |
| CYFIP1 | 208923_PM_at | –14.34 | 0.080 | –17.77 | 0.006 |
| WASF1 | 204165_PM_at | 4.59 | 0.076 | 2.54 | 0.270 |
The ARP2/3 complex, which stimulates de novo actin nucleation and polymerization to generate F-actin branched filament networks that modulate spine morphogenesis, is composed of seven subunits (11). The ACTR2 and ACTR3 transcripts encode the ARP2 and ARP3 subunits, which function as the ATP-binding component of the complex. In layer 3 pyramidal cells, mean transcript levels were significantly lower for both ACTR2 (−10.9%; F=11.4, df=1, 70, p=0.001) and ACTR3 (−15.2%; F=16.9, df=1, 70, p<0.001) in the schizophrenia subjects (Figure 2). The five ARPC subunits of the ARP2/3 complex are critical for actin binding and nucleation. In subjects with schizophrenia, mean transcript levels were lower for ARPC2 (−14.9%; F=12.0, df=1, 69, p=0.001), ARPC3 (−15.9%; F=9.3, df=1, 70, p=0.003), ARPC4 (−11.2%; F=17.4, df=1, 69, p<0.001), and ARPC5 (−10.2%; F=6.8, df=1, 68, p=0.011). The mean levels of the two human isoforms of ARPC1 (ARPC1A and ARPC1B) did not differ significantly between subject groups.
FIGURE 2. Microarray Analyses of ARP2/3 Complex Signaling Pathway mRNA Levels in Dorsolateral Prefrontal Cortex Deep Layer 3 Pyramidal Cells in Matched Pairs of Schizophrenia and Unaffected Comparison Subjectsa
a Log2-transformed microarray signals of ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, CTTN, WASL, CYFIP1, and WASF1 mRNAs in dorsolateral prefrontal cortex deep layer 3 pyramidal cells, for schizophrenia subjects relative to matched unaffected comparison subjects plotted for each pair. The data points below the diagonal unity line indicate lower mRNA signal in the schizophrenia subject relative to the matched comparison subject and vice versa. The percent difference in schizophrenia relative to unaffected comparison subject group means and the results of primary statistical analysis are provided for each quantified mRNA.
The ARP2/3 complex is regulated by nucleation promotion factors, including cortactin (CTTN), Neural Wiskott-Aldrich syndrome (N-WASP) proteins, and WASP family Verprolin-homologous (WAVE) proteins, such as WAVE1, which is modulated by cytoplasmic FMR1 interacting protein 1 (CYFIP1) (11, 22). In layer 3 pyramidal cells, mean CTTN transcript levels were lower in schizophrenia subjects, although this difference did not achieve statistical significance (−16.4%; F=3.9, df=1, 70, p=0.053). Mean transcript levels for WASL, which encodes N-WASP, were lower in schizophrenia (−10.1%; F=7.69, df=1, 69, p=0.007). For the WAVE complex, mean CYFIP1 transcript levels were lower in schizophrenia (−14.3%; F=4.7, df=1, 68, p=0.033), whereas mean transcript levels for WAVE1 (encoded by WASF1) were unaltered (4.6%; F=2.3, df=1, 70, p=0.134).
Effects of Comorbid Factors on ARP2/3 Complex Signaling Pathway Transcripts
Levels of ARP2/3 complex signaling pathway mRNAs that differed between subject groups did not differ among the schizophrenia subjects as a function of diagnosis of schizoaffective disorder; history of substance dependence or abuse; use of nicotine, antipsychotics, antidepressants, or benzodiazepines and/or sodium valproate at the time of death; or death by suicide (see Figure S1 in the online data supplement ), with the exception that schizophrenia subjects with a history of substance dependence or abuse had significantly lower ARPC4 (F=16.74, df=1, 34, p=0.001) and ARPC5 (F=5.96, df=1, 33, p=0.020) mRNA levels relative to those without such a history.
Effects of Antipsychotic Exposure on ARP2/3 Transcripts in Monkeys
Transcript levels for ARP2/3 complex signaling pathway in DLPFC layer 3 pyramidal cells did not differ significantly among monkeys chronically exposed to olanzapine, haloperidol, or placebo (see Figure S2 in the online data supplement ).
Cellular Specificity of Altered Expression ARP2/3 Complex Signaling Pathway Transcripts in Schizophrenia
To determine whether these transcript alterations in the ARP2/3 complex signaling pathway were also present in other cell types, we conducted similar microarray analyses in DLPFC layer 5 pyramidal cells. Using a false discovery rate of 5%, each probe set in the ARP2/3 complex signaling pathway showed the same pattern of down-regulation in both layer 5 and layer 3 pyramidal cells in schizophrenia; probe sets for two transcripts (CTTN and CYFIP1) that only approached statistical significance in layer 3 were clearly significantly lower in layer 5 pyramidal cells (Table 2). Consistent with these findings, ANCOVA analyses revealed lower mean mRNA levels for the ATP-binding component of the complex (ACTR2 and ACTR3) and for the subunits that mediate actin binding and nucleation (ARPC2, ARPC3, ARPC4, and ARPC5) (Figure 3). In addition, mean mRNA levels of the nucleation promotion factors (CTTN, WASL, and CYFIP1) were also lower (Figure 3).
FIGURE 3. Microarray Analyses of ARP2/3 Complex Signaling Pathway mRNA Levels in Dorsolateral Prefrontal Cortex Layer 5 Pyramidal Cells in Matched Pairs of Schizophrenia and Unaffected Comparison Subjectsa
a Log2-transformed microarray signals of ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, CTTN, WASL, CYFIP1, and WASF1 mRNAs in dorsolateral prefrontal cortex layer 5 pyramidal cells, for schizophrenia subjects relative to matched unaffected comparison subjects plotted for each pair. The data points below the diagonal unity line indicate lower mRNA signal in the schizophrenia subject relative to the matched comparison subject and vice versa. The percent difference in schizophrenia relative to unaffected comparison subject group means and the results of primary statistical analysis are provided for each quantified mRNA.
We also evaluated expression of transcripts in parvalbumin interneurons in a subset of subject pairs using data from an existing microarray data set (21). With the exception of ARPC3 mRNA, which was significantly lower in parvalbumin interneurons (−51.5%; F=7.4, df=1, 26, p=0.012), mean mRNA levels of ARP2/3 complex signaling pathway transcripts in layer 3 parvalbumin neurons did not differ significantly between subject groups. These findings do not appear to be false negatives due to a smaller sample size, because in these same 14 subject pairs, multiple transcripts were significantly down-regulated in layer 3 pyramidal cells in schizophrenia: ACTR2 (−12.7%; p=0.04), ACTR3 (−20.0%; p=0.002), ARPC2 (−21.3%; p=0.003), ARPC4 (−13.8%; p=0.009), and WASL (−14.5%; p=0.019); levels of two other transcripts were also lower but did not achieve statistical significance: ARPC3 (−18.2%; p=0.073) and CTTN (−24.6%; p=0.062). These findings suggest that within the same cortical layer, most alterations in the ARP2/3 complex signaling pathway are specific to, or at least enriched in, pyramidal cells relative to parvalbumin interneurons. However, caution is warranted in interpreting these findings given the technical caveat that the most severely affected parvalbumin interneurons may not have been identifiable for capture by laser microdissection (21).
ARP2/3 Complex Signaling Pathway Transcripts in DLPFC Gray Matter in Schizophrenia
To further test the cell-type specificity of alterations in the ARP2/3 complex signaling pathway, we analyzed transcript levels in total DLPFC gray matter by qPCR (see Table S3 in the online data supplement ) in the same 36 pairs of subjects used for the pyramidal cell profiling. In contrast to the findings in pyramidal cells, mean mRNA levels in the schizophrenia subjects were higher for ARPC3 (3.8%; F=3.2, df=1, 69, p=0.034), CTTN (5.9%; F=7.6, df=1, 67, p=0.007), and WASL (3.4%; F=6.5, df=1, 70, p=0.013). None of the other transcripts significantly differed between subject groups, with the exception of mRNA levels for ARPC5, which were significantly lower (−6.0%; F=5.4, df=1, 68, p=0.023), but this decrement was smaller than in pyramidal cells.
To control for possible false negative findings due to sample size, the transcripts in the ARP2/3 complex signaling pathway were evaluated in DLPFC gray matter in a larger subject cohort (N=62 pairs). Of the nine transcripts that were significantly lower in layer 3 and/or 5 pyramidal neurons in subjects with schizophrenia, three were increased in expression, three were not different, and three were decreased, but the deficits were much smaller than in pyramidal cells (see Table S3).
Discussion
Our results identify lower mRNA levels of multiple subunits of the ARP2/3 complex, and of nucleation promotion factors that regulate the activity of the ARP2/3 complex, in DLPFC deep layer 3 and 5 pyramidal cells in schizophrenia (Figure 1B). These alterations appear to reflect the disease process of schizophrenia, as they were not attributable to chronic treatment with antipsychotic medications, other factors frequently comorbid with schizophrenia, or potential confounders. In contrast, expression levels of ARP2/3 complex signaling pathway transcripts were up-regulated, not altered, or only modestly lower in DLPFC parvalbumin interneurons and DLPFC gray matter. Furthermore, the expression deficits in ARP2/3 complex signaling pathways in pyramidal cells do not appear to reflect nonspecific factors, as multiple other transcripts are up-regulated in these neurons (19, 23). Because the ARP2/3 complex signaling pathway is a critical determinant of F-actin nucleation and polymerization, dysregulation of the ARP2/3 complex signaling pathway in schizophrenia may contribute to actin cytoskeleton impairments and spine deficits in DLPFC pyramidal cells.
Predicted Consequences of Down-Regulated ARP2/3 Complex Signaling Pathway in DLPFC Pyramidal Cells
In DLPFC pyramidal cells from schizophrenia subjects, the down-regulation in mRNA levels for multiple ARP2/3 complex transcripts (e.g., ACTR2, ARPC2, ARPC3) would be predicted to contribute to spine deficits by suppressing de novo actin polymerization, which generates the branched actin filament networks required for spine formation (Figure 1B) (24–26). In addition, high concentrations of the ARP2/3 complex are found in the spine head, where it is localized proximal to F-actin filaments (27). Therefore, reduced gene expression of ARP2/3 complex subunits would likely impair the actin nucleation and cross-linking of F-actin filaments, which are critical for the activity-dependent structural plasticity of spines, contributing to decreased spine stability and ultimately spine loss.
The ARP2/3 complex also acts as a molecular hub downstream of several signaling pathways that promote the structural stabilization of F-actin filaments necessary for spine maintenance (28–31). For example, nucleation promotion factors are required to activate the intrinsically inactive ARP2/3 complex; specifically, the nucleation promotion factors N-WASP, cortactin, and CYFIP1 bring the ARP2/3 complex and F-actin monomers together to initiate the synthesis of new F-actin filaments (32). Therefore, the down-regulation of these nucleation promotion factors in schizophrenia may further diminish ARP2/3 complex activity in the following ways (Figure 1B).
First, activation of ARP2/3 complex by N-WASP favors branch nucleation, which allows stabilization of newly synthesized F-actin filaments (33, 34); thus, lower levels of both N-WASP and the ARP2/3 complex in schizophrenia would likely result in reduced nucleation of spine precursors such as lamellipodia and filopodia. Indeed, knockdown of endogenous N-WASP by RNA interference has been shown to decrease dendritic spine number in hippocampal pyramidal neurons (34).
Second, CYFIP1 acts through the WAVE regulatory complex and cortactin to regulate the actin-nucleating activity of the ARP2/3 complex (11, 22, 35); thus lower levels of CYFIP1, cortactin, and ARP2/3 complex subunits would further impair F-actin filament turnover and actin cytoskeleton dynamics, which are necessary for formation of dendritic spines.
Third, CYFIP1 inhibits dendritic protein translation in an activity-dependent fashion and promotes actin cytoskeleton remodeling (29) by acting downstream of brain-derived neurotrophic factor (BDNF) and its postsynaptic partner TrkB, which are crucial for spine enlargement and stabilization (36). Thus, the lower levels of both BDNF and TrkB in the DLPFC of subjects with schizophrenia (37, 38) would likely further exacerbate the negative impact of impaired ARP2/3 complex signaling on spine number in DLPFC pyramidal cells.
Laminar-Specificity of Spine Pathology in DLPFC Pyramidal Cells in Schizophrenia
Previous postmortem studies have revealed lower basilar dendritic spine density on deep layer 3, but not on layer 5 or 6 pyramidal neurons, from the same subjects with schizophrenia (16, 17). Given this apparent laminar specificity of spine deficits, we expected that alterations in the ARP2/3 complex signaling pathway would be more marked in deep layer 3 than layer 5 pyramidal cells. However, the presence of ARP2/3 complex signaling pathway alterations in pyramidal cells in both layers suggests that these deficits 1) are not a secondary consequence of a reduced number of pyramidal cell dendritic spines and 2) may be a necessary but not a sufficient cause of reduced spine density.
The prominence of spine deficits in deep layer 3 pyramidal cells may be due to other factors upstream of the ARP2/3 complex, such as disturbances in certain components of the Rho family GTPase cell division cycle 42 (CDC42) signaling pathway (23, 39) for the following reasons. First, some of the components of this pathway, such as CDC42 effector proteins (CDC42EPs), are preferentially expressed in layers 2–3 of the DLPFC (40) and the CDC42-CDC42EP pathway is dysregulated in DLPFC layer 3 pyramidal cells in schizophrenia (23, 39). Second, another CDC42 signaling pathway (CDC42-p21-activated serine/threonine protein kinases [PAK]-LIM domain-containing serine/threonine protein kinases [LIMK] signaling pathway) is also altered in DLPFC layer 3 pyramidal cells; these alterations could destabilize actin dynamics by reducing F-actin turnover through cofilin, a family of actin depolymerizing proteins (23). Third, in addition to disrupting the spine cytoskeleton in their own right, these impairments in CDC42 signaling could magnify the impact of the alterations in the ARP2/3 complex signaling pathway. For example, the intrinsically autoinhibited N-WASP is directly activated by CDC42 (41, 42); thus, deficits in CDC42 signaling could exacerbate the consequences of deficits in the N-WASP-ARP2/3 complex cascade. In summary, the prominence of spine deficits in DLPFC deep layer 3 pyramidal cells in schizophrenia may reflect the convergent effects of alterations in several different signaling pathways, each of which could destabilize the actin cytoskeleton.
Do Actin Cytoskeleton Impairments Reflect Genetic Liability for Schizophrenia?
The altered expression of genes in the CDC42 and ARP2/3 signaling pathways may be related to genetic risk factors for schizophrenia. For example, the interaction of single-nucleotide polymorphisms in CYFIP1, ARP2, and ARP3 has been reported to be associated with an increased risk for schizophrenia (43). Genome-wide association studies in schizophrenia have revealed enrichment of risk variants in genes whose products are involved in the activity-regulated cytoskeleton-associated scaffold protein (ARC), postsynaptic density (PSD) protein complex, and complement component 4 (C4) genes, which are heavily localized to dendritic spines and neuronal synapses (44–47). Aberrant expression of these gene products during postnatal development may exacerbate spine pruning and synapse loss in subjects with schizophrenia. In addition, de novo mutations in schizophrenia are overrepresented among loci encoding cytoskeleton-associated proteins that regulate actin (48). These genetic findings are consistent with the idea that abnormalities intrinsic to DLPFC deep layer 3 pyramidal cells represent an “upstream” component in the disease process of schizophrenia (49, 50). That is, variants or mutations in genes that regulate the actin cytoskeleton, in concert with altered expression of cell type-specific gene products, may be the pathogenic substrate for spine deficits in schizophrenia.
Implications for the Disease Process of Schizophrenia
The disease process of schizophrenia has been proposed to involve pathology in the DLPFC, which contributes to the pathophysiology of psychosis (9). This hypothesis is supported from a temporal perspective by findings that cognitive deficits, including those that depend on DLPFC circuitry, emerge and progress years before the onset of psychosis (51, 52). In addition, activation of the DLPFC during cognitive tasks is inversely related to measures of striatal dopaminergic function in subjects with schizophrenia (15). Evidence for causality in this association was recently provided by findings that deletion of the ARP2/3 complex in mice, resulting in cortical spine deficits, also leads to a subcortical hyperdopaminergia that improves with antipsychotic medications and is reversible with restoration of prefrontal ARP2/3 expression (13). The findings of the present study demonstrate that this mechanism is plausible in schizophrenia by showing that the ARP2/3 complex signaling pathway is altered in DLPFC pyramidal cells. The resulting loss of dendritic spines on layer 3 pyramidal cells in the DLPFC could represent an upstream pathology that eventually gives rise to excessive dopamine function in the associative striatum and the appearance of psychosis (10).
Acknowledgments
The authors gratefully acknowledge Mary Brady, B.S., for technical assistance.
Supplementary Material
File (appi.ajp.2016.16020204.ds001.pdf)
- Download
- 852.21 KB
References
1.
Elvevåg B, Goldberg TE: Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000; 14:1–21
2.
Davidson M, Reichenberg A, Rabinowitz J, et al: Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 1999; 156:1328–1335
3.
Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153:321–330
4.
Lesh TA, Niendam TA, Minzenberg MJ, et al: Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology 2011; 36:316–338
5.
Arnsten AF, Wang MJ, Paspalas CD: Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses. Neuron 2012; 76:223–239
6.
Goldman-Rakic PS: Cellular basis of working memory. Neuron 1995; 14:477–485
7.
Glausier JR, Lewis DA: Dendritic spine pathology in schizophrenia. Neuroscience 2013; 251:90–107
8.
Howes OD, Kambeitz J, Kim E, et al: The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012; 69:776–786
9.
Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44:660–669
10.
Lewis DA, Gonzalez-Burgos G: Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006; 12:1016–1022
11.
Goley ED, Welch MD: The ARP2/3 complex: an actin nucleator comes of age. Nat Rev Mol Cell Biol 2006; 7:713–726
12.
Hotulainen P, Hoogenraad CC: Actin in dendritic spines: connecting dynamics to function. J Cell Biol 2010; 189:619–629
13.
Kim IH, Rossi MA, Aryal DK, et al: Spine pruning drives antipsychotic-sensitive locomotion via circuit control of striatal dopamine. Nat Neurosci 2015; 18:883–891
14.
Kim IH, Racz B, Wang H, et al: Disruption of Arp2/3 results in asymmetric structural plasticity of dendritic spines and progressive synaptic and behavioral abnormalities. J Neurosci 2013; 33:6081–6092
15.
Meyer-Lindenberg A, Miletich RS, Kohn PD, et al: Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002; 5:267–271
16.
Glantz LA, Lewis DA: Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000; 57:65–73
17.
Kolluri N, Sun Z, Sampson AR, et al: Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 2005; 162:1200–1202
18.
Volk DW, Chitrapu A, Edelson JR, et al: Molecular mechanisms and timing of cortical immune activation in schizophrenia. Am J Psychiatry 2015; 172:1112–1121
19.
Arion D, Corradi JP, Tang S, et al: Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder. Mol Psychiatry 2015; 20:1397–1405
20.
Datta D, Arion D, Lewis DA: Developmental expression patterns of GABAA receptor subunits in layer 3 and 5 pyramidal cells of monkey prefrontal cortex. Cereb Cortex 2015; 25:2295–2305
21.
Georgiev D, Arion D, Enwright JF, et al: Lower gene expression for KCNS3 potassium channel subunit in parvalbumin-containing neurons in the prefrontal cortex in schizophrenia. Am J Psychiatry 2014; 171:62–71
22.
Chen B, Brinkmann K, Chen Z, et al: The WAVE regulatory complex links diverse receptors to the actin cytoskeleton. Cell 2014; 156:195–207
23.
Datta D, Arion D, Corradi JP, et al: Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia. Biol Psychiatry 2015; 78:775–785
24.
Blanchoin L, Amann KJ, Higgs HN, et al: Direct observation of dendritic actin filament networks nucleated by Arp2/3 complex and WASP/Scar proteins. Nature 2000; 404:1007–1011
25.
Korobova F, Svitkina T: Arp2/3 complex is important for filopodia formation, growth cone motility, and neuritogenesis in neuronal cells. Mol Biol Cell 2008; 19:1561–1574
26.
Rouiller I, Xu XP, Amann KJ, et al: The structural basis of actin filament branching by the Arp2/3 complex. J Cell Biol 2008; 180:887–895
27.
Rácz B, Weinberg RJ: Organization of the Arp2/3 complex in hippocampal spines. J Neurosci 2008; 28:5654–5659
28.
Clement JP, Aceti M, Creson TK, et al: Pathogenic SYNGAP1 mutations impair cognitive development by disrupting maturation of dendritic spine synapses. Cell 2012; 151:709–723
29.
De Rubeis S, Pasciuto E, Li KW, et al: CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation. Neuron 2013; 79:1169–1182
30.
Hayashi-Takagi A, Takaki M, Graziane N, et al: Disrupted-in-schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. Nat Neurosci 2010; 13:327–332
31.
Penzes P, Beeser A, Chernoff J, et al: Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rho-GEF kalirin. Neuron 2003; 37:263–274
32.
Pollard TD: Regulation of actin filament assembly by Arp2/3 complex and formins. Annu Rev Biophys Biomol Struct 2007; 36:451–477
33.
Miki H, Sasaki T, Takai Y, et al: Induction of filopodium formation by a WASP-related actin-depolymerizing protein N-WASP. Nature 1998; 391:93–96
34.
Wegner AM, Nebhan CA, Hu L, et al: N-wasp and the arp2/3 complex are critical regulators of actin in the development of dendritic spines and synapses. J Biol Chem 2008; 283:15912–15920
35.
Chia PH, Chen B, Li P, et al: Local F-actin network links synapse formation and axon branching. Cell 2014; 156:208–220
36.
Rex CS, Lin CY, Kramár EA, et al: Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus. J Neurosci 2007; 27:3017–3029
37.
Hashimoto T, Bergen SE, Nguyen QL, et al: Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 2005; 25:372–383
38.
Weickert CS, Hyde TM, Lipska BK, et al: Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003; 8:592–610
39.
Ide M, Lewis DA: Altered cortical CDC42 signaling pathways in schizophrenia: implications for dendritic spine deficits. Biol Psychiatry 2010; 68:25–32
40.
Arion D, Unger T, Lewis DA, et al: Molecular markers distinguishing supragranular and infragranular layers in the human prefrontal cortex. Eur J Neurosci 2007; 25:1843–1854
41.
Abdul-Manan N, Aghazadeh B, Liu GA, et al: Structure of Cdc42 in complex with the GTPase-binding domain of the “Wiskott-Aldrich syndrome” protein. Nature 1999; 399:379–383
42.
Rohatgi R, Ma L, Miki H, et al: The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell 1999; 97:221–231
43.
Yoon KJ, Nguyen HN, Ursini G, et al: Modeling a genetic risk for schizophrenia in iPSCs and mice reveals neural stem cell deficits associated with adherens junctions and polarity. Cell Stem Cell 2014; 15:79–91
44.
Kirov G, Pocklington AJ, Holmans P, et al: De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 2012; 17:142–153
45.
Purcell SM, Moran JL, Fromer M, et al: A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014; 506:185–190
46.
Schizophrenia Working Group of the Psychiatric Genomics Consortium: Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511:421–427
47.
Sekar A, Bialas AR, de Rivera H, et al: Schizophrenia risk from complex variation of complement component 4. Nature 2016; 530:177–183
48.
Fromer M, Pocklington AJ, Kavanagh DH, et al: De novo mutations in schizophrenia implicate synaptic networks. Nature 2014; 506:179–184
49.
Gonzalez-Burgos G, Cho RY, Lewis DA: Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. Biol Psychiatry 2015; 77:1031–1040
50.
Lewis DA, Curley AA, Glausier JR, et al: Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 2012; 35:57–67
51.
Gur RC, Calkins ME, Satterthwaite TD, et al: Neurocognitive growth charting in psychosis spectrum youths. JAMA Psychiatry 2014; 71:366–374
52.
Reichenberg A, Caspi A, Harrington H, et al: Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry 2010; 167:160–169
Information & Authors
Information
Published In
History
Received: 15 February 2016
Revision received: 12 April 2016
Accepted: 20 May 2016
Published online: 13 August 2016
Published in print: February 01, 2017
Authors
Competing Interests
Dr. Lewis has received investigator-initiated research support from Pfizer and has served as a consultant in the areas of target identification and validation and new compound development for Autifony, Bristol-Myers Squibb, Concert Pharmaceuticals, and Sunovion. The other authors report no financial relationships with commercial interests.
Funding Information
National Institute of Mental Health10.13039/100000025: MH043784, MH103204, MH100066
Supported by NIH grants MH103204 (to Dr. Lewis), MH043784 (to Dr. Lewis), and MH100066 (to Dr. Volk).Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
PDF/ePub
View PDF/ePubGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).